|
FY2025
12 months to Dec 31, 2025
|
|
|---|---|
| Revenues: | |
| Revenue | |
| Operating Expenses: | |
| Research and development | |
| Legal and professional | |
| General and administrative | |
| Share-Based Payment Arrangement, Noncash Expense | |
| Advisory fees – principally related parties | |
| Total Operating Expenses | |
| Loss From Operations | |
| Other Income (Expense): | |
| Interest and other income | |
| Grant income | |
| Amortization of debt issuance costs | |
| Interest expense | |
| Loss on change in fair value of derivative liability related to sales of common stock through equity line of credit | |
| Net Loss | |
| Basic net loss per common share | |
| Diluted net loss per common share | |
| Weighted average shares used in computing basic net loss per common share | |
| Weighted average shares used in computing diluted net loss per common share |
Loading...
